Unknown

Dataset Information

0

Myeloid-derived growth factor alleviates non-alcoholic fatty liver disease alleviates in a manner involving IKKβ/NF-κB signaling.


ABSTRACT: Whether bone marrow modulates systemic metabolism remains unknown. Our recent study suggested that myeloid-derived growth factor (MYDGF) improves insulin resistance. Here, we found that myeloid cell-specific MYDGF deficiency aggravated hepatic inflammation, lipogenesis, and steatosis, and show that myeloid cell-derived MYDGF restoration alleviated hepatic inflammation, lipogenesis, and steatosis. Additionally, recombinant MYDGF attenuated inflammation, lipogenesis, and fat deposition in primary mouse hepatocytes (PMHs). Importantly, inhibitor kappa B kinase beta/nuclear factor-kappa B (IKKβ/NF-κB) signaling is involved in protection of MYDGF on non-alcoholic fatty liver disease (NAFLD). These data revealed that myeloid cell-derived MYDGF alleviates NAFLD and inflammation in a manner involving IKKβ/NF-κB signaling, and serves as a factor involved in the crosstalk between the liver and bone marrow that regulates liver fat metabolism. Bone marrow functions as an endocrine organ and serves as a potential therapeutic target for metabolic disorders.

SUBMITTER: Ding Y 

PROVIDER: S-EPMC10293205 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Myeloid-derived growth factor alleviates non-alcoholic fatty liver disease alleviates in a manner involving IKKβ/NF-κB signaling.

Ding Yan Y   Xu Xiaoli X   Meng Biying B   Wang Li L   Zhu Biao B   Guo Bei B   Zhang Jiajia J   Xiang Lin L   Dong Jing J   Liu Min M   Xiang Guangda G  

Cell death & disease 20230626 6


Whether bone marrow modulates systemic metabolism remains unknown. Our recent study suggested that myeloid-derived growth factor (MYDGF) improves insulin resistance. Here, we found that myeloid cell-specific MYDGF deficiency aggravated hepatic inflammation, lipogenesis, and steatosis, and show that myeloid cell-derived MYDGF restoration alleviated hepatic inflammation, lipogenesis, and steatosis. Additionally, recombinant MYDGF attenuated inflammation, lipogenesis, and fat deposition in primary  ...[more]

Similar Datasets

| S-EPMC7070172 | biostudies-literature
| S-EPMC9171502 | biostudies-literature
| S-EPMC4674875 | biostudies-literature
| S-EPMC10968678 | biostudies-literature
2019-04-12 | GSE129678 | GEO
| S-EPMC8184690 | biostudies-literature
| S-EPMC6124152 | biostudies-literature
| S-EPMC9483129 | biostudies-literature
| S-EPMC5361650 | biostudies-literature
| S-EPMC9696864 | biostudies-literature